FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.
A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
Over the past decade or so, prostate-specific membrane antigen (PSMA) PET/CT has increasingly replaced conventional imaging in men with biochemical recurrence after radical prostatectomy. PSMA PET/CT ...
By Puyaan Singh and Sahil Pandey March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ...
The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Award, which will ...
Clinical node involvement on preoperative PSMA-PET predicts radiographic recurrence for pN1 prostate cancer patients following RP/PLND.
The ongoing Daro-PET study set out to evaluate the ability of the oral androgen receptor inhibitor darolutamide (Nubeqa) to ...
LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...
Surgery patients staged with PSMA-PET appear to have a lower risk of early BCR than those staged with conventional imaging. Early oncologic outcomes after radical prostatectomy (RP) for very high risk ...
A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results